VEA
CNTA

Virtus ETF Advisers’s Centessa Pharmaceuticals CNTA Stock Holding History

Virtus ETF Advisers’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,214
Closed -$70.6K – 506
2024
Q4 		$70.6K Sell
4,214
-5,071
-55% -$84K 0.03% 374
2024
Q3 		$148K Buy
9,285
+169
+2% +$2.07K 0.07% 328
2024
Q2 		$82.3K Buy
+9,116
New +$86.5K 0.04% 394
2022
Q2 		– Sell
-13,969
Closed -$125K – 447
2022
Q1 		$125K Sell
13,969
-829
-6% -$7.56K 0.06% 255
2021
Q4 		$167K Buy
+14,798
New +$199K 0.06% 298

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virtus ETF Advisers's CNTA Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Centessa Pharmaceuticals (CNTA) in Q1 2025, closing a stake of 4,214 shares — an estimated $70.6K sold.

Virtus ETF Advisers first reported a position in CNTA in Q4 2021 and held it in 5 quarters. The position peaked at $167K in Q4 2021. 129 funds tracked by Wall St. Rank hold CNTA as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Centessa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 4,214 Centessa Pharmaceuticals shares in Q1 2025, an estimated $70.6K.
  • Virtus ETF Advisers first reported a position in Centessa Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Virtus ETF Advisers's Centessa Pharmaceuticals position peaked at $167K in Q4 2021.
  • 129 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.